Non-Dopaminergic Therapies

John G Nutt; Nicolaas I Bohnen

doi:10.3233/JPD-181472

Non-Dopaminergic Therapies

J Parkinsons Dis. 2018;8(s1):S73-S78. doi: 10.3233/JPD-181472.

Authors

John G Nutt^{1

2}, Nicolaas I Bohnen^{3

4

5

6}

Affiliations

¹ Department of Neurology, Oregon Health & Sciences University, Portland, OR, USA.
² Director Emeritus of the OHSU Parkinson Center and Movement Disorders Program, Oregon Health & Sciences University, Portland, OR, USA.
³ Radiology, University of Michigan, Ann Arbor, MI, USA.
⁴ Neurology, University of Michigan, Ann Arbor, MI, USA.
⁵ Neurology Service and GRECC, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, MI, USA.
⁶ Morris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, USA.

Abstract

Currently all aspects of Parkinson's disease (PD) treatment are less than ideal and would benefit from new interventions. We focus on problems associated with brain neurotransmitters amenable to more specific subreceptor and temporal manipulation. In addition, we consider potentially treatable CNS non-PD co-pathologies or co-morbidities that may exacerbate progression of various aspects of PD.

Keywords: Acetylcholine; GABA; GBA; cognition; diabetes mellitus; falls; freezing of gait; glymphatic clearance; small vessel disease; β-amyloid.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Depressive Disorder / complications
Depressive Disorder / drug therapy*
Disease Progression
Gait Disorders, Neurologic / complications
Gait Disorders, Neurologic / drug therapy*
Humans
Parkinson Disease / drug therapy*
Parkinson Disease / therapy*

Grants and funding

P50 NS091856/NS/NINDS NIH HHS/United States